Research programme: pain therapy - Arakis/Penwest
Latest Information Update: 23 Jan 2004
Price :
$50 *
At a glance
- Originator Penwest Pharmaceuticals; Sosei R&D
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 23 Jan 2004 Discontinued - Preclinical for Pain in USA (PO)
- 29 Nov 2001 Preclinical development for Pain in USA (PO)